Abgenomics Cooperatief U.a.

Bioalliance C.v.

Abgenomics International Inc.

Cho Pharma Inc.

Abgenomics Cooeperatief U.a.

Chiu-Chen Huang

Rong-Hwa Lin

Chung Nan Chang

Pei-Jiun Chen

Shih-Yao Lin

Yu-Chi Hsieh

Chi-Huey Wong

Nan-Horng Lin

Chien-Yu Chen

Han-Chung Wu

Yu-Ying Tsai

Shu-Hua Lee

Kuo-Ching Chu

Feng-Lin Chiang

Li-An Hu

The present disclosure relates to anti-SSEA4 antibodies and bindings fragments thereof comprising specific complementarity determining regions capable of high affinity binding to SSEA4 molecules and SSEA4-associated expressing tumor cells, such as breast cancer, pancreatic cancer, and renal cancer cells. The anti-SSEA4 antibodies and binding fragments induce ADCC or CDC effects in the targeted tumor cells and inhibit and/or reduce the cancer/tumor proliferation. The present disclosure also provides anti-SSEA4 antibodies and binding fragments thereof as a pharmaceutical composition for treating cancer. In addition, the anti-SSEA4 antibodies and binding fragments are useful in the diagnosis of cancers.

Antibodies, binding fragments, and methods of use

Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.

Methods of treating with anti-PSGL-1 antibodies

The present disclosure provides anti-folate receptor alpha (FRA) antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.

Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof

The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.

Hydrophilic self-immolative linkers and conjugates thereof

Methods of treating GVHD and transplant rejection with anti-PSGL-1 antibodies

Anti-PSGL-1 antibodies and methods of inducing cell death of an activated T cell

Anti-PSGL-1 antibodies

Methods of inducing cell death of an activated T cell with anti-PSGL-1 antibodies

Growing community of inventors

Taipei, Taiwan

Chiu-Chen Huang